S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:ANEB

Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis

$2.72
-0.06 (-2.16%)
(As of 02/29/2024 ET)
Today's Range
$2.72
$3.14
50-Day Range
$2.34
$3.00
52-Week Range
$1.62
$4.05
Volume
2,277 shs
Average Volume
5,389 shs
Market Capitalization
$69.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Anebulo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
145.1% Upside
$6.67 Price Target
Short Interest
Healthy
0.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Anebulo Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.47) to ($0.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.93 out of 5 stars

Medical Sector

593rd out of 958 stocks

Pharmaceutical Preparations Industry

284th out of 450 stocks


ANEB stock logo

About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

ANEB Stock Price History

ANEB Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Anebulo Pharmaceuticals, Inc. (ANEB)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Anebulo Pharmaceuticals Inc ANEB
Anebulo Pharmaceuticals Announces New CEO
H.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)
See More Headlines
Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
2/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANEB
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.67
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+145.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-11,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.25 per share

Miscellaneous

Free Float
3,614,000
Market Cap
$69.72 million
Optionable
Not Optionable
Beta
-1.08
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Joseph F. Lawler M.D. (Age 52)
    Ph.D., Founder & Chairman
    Comp: $11k
  • Dr. Kenneth C. Cundy Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $425.15k
  • Mr. Richard Anthony Cunningham (Age 53)
    CEO & Director
  • Mr. Daniel V. George (Age 54)
    Principal Accounting Officer, Acting CFO & Secretary
  • Mr. Scott L. Anderson
    Head of Investor Relations & Public Affairs














ANEB Stock Analysis - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings
or view top-rated stocks.

What is Anebulo Pharmaceuticals' stock price target for 2024?

3 brokers have issued 1 year price objectives for Anebulo Pharmaceuticals' shares. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 145.1% from the stock's current price.
View analysts price targets for ANEB
or view top-rated stocks among Wall Street analysts.

How have ANEB shares performed in 2024?

Anebulo Pharmaceuticals' stock was trading at $2.42 at the beginning of 2024. Since then, ANEB shares have increased by 12.4% and is now trading at $2.72.
View the best growth stocks for 2024 here
.

Are investors shorting Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals saw a increase in short interest in February. As of February 15th, there was short interest totaling 3,000 shares, an increase of 11.1% from the January 31st total of 2,700 shares. Based on an average trading volume of 8,800 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the shares of the company are short sold.
View Anebulo Pharmaceuticals' Short Interest
.

When is Anebulo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ANEB earnings forecast
.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04.

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an initial public offering on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

Who are Anebulo Pharmaceuticals' major shareholders?

Anebulo Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LVW Advisors LLC (2.51%) and Vanguard Group Inc. (0.60%).
View institutional ownership trends
.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANEB) was last updated on 2/29/2024 by MarketBeat.com Staff